Verona Pharma's VRNA short percent of float has fallen 11.62% since its last report. The company recently reported that it ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 biotech stocks screaming a buy. On June 17, Roth Capital increased its price ...

Verona Pharma Announces June 2025 Investor Conference Participation. LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the ...

A high-level overview of Verona Pharma plc (VRNA) stock. View (VRNA) real-time stock price, chart, news, analysis, analyst reviews and more.

Verona Pharma (VRNA) is showing exceptional technical strength, hitting a new high in morning trading on June 24. ・The stock has a 100% technical “Buy” signal via Barchart. ・The stock has surged 515% ...

Review Verona Pharma PLC ADR (VRNA:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Verona Pharma's plans to transform COPD treatment with recently approved Ohtuvayre look like they are on course, given early sales figures. Skip to main content Tuesday 24 June 2025 ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.

Read about Verona Pharma PLC ADR (VRNA:XNAS) stock and today's latest news and financial updates. VRNA - Verona Pharma PLC ADR News | Morningstar Morningstar brands and products ...

Discover real-time Verona Pharma plc American Depositary Share (VRNA) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.